The vaccines are: Enzira (Pfizer), Fluarix (GlaxoSmithKline), Fluvirin (Novartis), Imuvac and Influvac (Abbott), Inactivated Influenza Vaccine BP and Intanza (Sanofi-Pasteur MSD), and the live-attenuated intranasal preparation Fluenz (AstraZeneca), for use only in children and adolescents.
Agrippal and Optaflu (Novartis), Inflexal V and Viroflu (Janssen-Cilag) are expected to be available later in October.
The cell-culture-derived vaccine, Preflucel, is no longer available.
In line with EMA/WHO recommendations for the 2012/2013 season, the vaccines contain the same H1N1-like virus strain as last season (A/California/7/2009), with two new strains:
• A/Victoria/361/2011 as the H3N2-like component
• B/Wisconsin/1/2010 as the influenza B component.
Updated 1 November 2012
Prescribing information for egg-free vaccine released
Novartis has released 2012/2013 prescribing information for its flu vaccines Agrippal and Optaflu, but reports that both preparations are currently out of stock.